Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

303 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Bioinformatics for cancer immunotherapy target discovery.
Olsen LR, Campos B, Barnkob MS, Winther O, Brusic V, Andersen MH. Olsen LR, et al. Among authors: andersen mh. Cancer Immunol Immunother. 2014 Dec;63(12):1235-49. doi: 10.1007/s00262-014-1627-7. Epub 2014 Oct 26. Cancer Immunol Immunother. 2014. PMID: 25344903 Review.
Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.
Andersen MH, Pedersen LO, Becker JC, Straten PT. Andersen MH, et al. Cancer Res. 2001 Feb 1;61(3):869-72. Cancer Res. 2001. PMID: 11221872
In situ cytokine therapy: redistribution of clonally expanded T cells.
thor Straten P, Guldberg P, Schrama D, Andersen MH, Moerch U, Seremet T, Siedel C, Reisfeld RA, Becker JC. thor Straten P, et al. Among authors: andersen mh. Eur J Immunol. 2001 Jan;31(1):250-8. doi: 10.1002/1521-4141(200101)31:1<250::AID-IMMU250>3.0.CO;2-8. Eur J Immunol. 2001. PMID: 11265641
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.
Andersen MH, Pedersen LO, Capeller B, Bröcker EB, Becker JC, thor Straten P. Andersen MH, et al. Cancer Res. 2001 Aug 15;61(16):5964-8. Cancer Res. 2001. PMID: 11507035
[Immunotherapy of cancer].
Andersen MH, Schmidt H, Gehl J, von der Maase H, Straten P. Andersen MH, et al. Ugeskr Laeger. 2002 Jun 3;164(23):3008-16. Ugeskr Laeger. 2002. PMID: 12082849 Review. Danish.
HLA-B35-restricted immune responses against survivin in cancer patients.
Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. Reker S, et al. Among authors: andersen mh. Int J Cancer. 2004 Mar 1;108(6):937-41. doi: 10.1002/ijc.11634. Int J Cancer. 2004. PMID: 14712500
Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P, thor Straten P. Andersen MH, et al. Semin Cancer Biol. 2003 Dec;13(6):449-59. doi: 10.1016/j.semcancer.2003.09.009. Semin Cancer Biol. 2003. PMID: 15001164 Review.
The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses.
Andersen MH, Reker S, Becker JC, thor Straten P. Andersen MH, et al. J Invest Dermatol. 2004 Feb;122(2):392-9. doi: 10.1046/j.0022-202X.2004.22242.x. J Invest Dermatol. 2004. PMID: 15009721
Immunogenicity of constitutively active V599EBRaf.
Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, Berger TG, Schadendorf D, Trefzer U, Bröcker EB, Straten Pt, Rapp UR, Becker JC. Andersen MH, et al. Cancer Res. 2004 Aug 1;64(15):5456-60. doi: 10.1158/0008-5472.CAN-04-0937. Cancer Res. 2004. PMID: 15289355
Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients.
Meier A, Reker S, Svane IM, Holten-Andersen L, Becker JC, Søndergaard I, Andersen MH, Thor Straten P. Meier A, et al. Among authors: andersen mh. Cancer Immunol Immunother. 2005 Mar;54(3):219-28. doi: 10.1007/s00262-004-0578-9. Epub 2004 Oct 2. Cancer Immunol Immunother. 2005. PMID: 15580499
303 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback